Enzymotec Ltd. (NASDAQ:ENZY)‘s stock had its “hold” rating reaffirmed by stock analysts at Jefferies Group in a research report issued on Monday. They currently have a $7.00 target price on the stock, down from their prior target price of $8.00. Jefferies Group’s price objective suggests a potential upside of 11.11% from the company’s current price.

ENZY has been the subject of a number of other reports. Wells Fargo & Co. downgraded Enzymotec from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 17th. Zacks Investment Research raised Enzymotec from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th.

Shares of Enzymotec (NASDAQ:ENZY) opened at 6.30 on Monday. The stock has a market cap of $143.38 million, a PE ratio of 58.88 and a beta of 1.26. Enzymotec has a 52-week low of $5.20 and a 52-week high of $10.32. The company’s 50-day moving average price is $6.65 and its 200-day moving average price is $7.66.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings data on Wednesday, November 16th. The company reported $0.03 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.04. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $13.29 million. Enzymotec had a return on equity of 1.95% and a net margin of 4.82%. Enzymotec’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 earnings per share. Analysts expect that Enzymotec will post $0.18 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Reiterates Hold Rating for Enzymotec Ltd. (ENZY)” was posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The original version of this story can be read at http://www.financial-market-news.com/jefferies-group-reiterates-hold-rating-for-enzymotec-ltd-enzy/1209813/.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENZY. Public Employees Retirement System of Ohio boosted its position in Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock valued at $294,000 after buying an additional 11,501 shares during the last quarter. Algert Global LLC raised its stake in shares of Enzymotec by 32.9% in the third quarter. Algert Global LLC now owns 50,566 shares of the company’s stock valued at $354,000 after buying an additional 12,520 shares during the period. Menta Capital LLC raised its stake in shares of Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock valued at $405,000 after buying an additional 5,362 shares during the period. Janus Capital Management LLC raised its stake in shares of Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the period. Finally, Van ECK Associates Corp raised its stake in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the period. 35.93% of the stock is owned by institutional investors.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

5 Day Chart for NASDAQ:ENZY

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.